Andrew C. Wang

Andrew C. Wang is a highly experienced scientist with a strong background in oncology chemical biology and biomedicine. Currently serving as the Director of Platform and Principal Scientist at Belharra Therapeutics since December 2021, Andrew has previously held positions as Principal Scientist and Senior Scientist at Pfizer from August 2017 to December 2021. Andrew's earlier career includes a postdoctoral role at Novartis Institutes for BioMedical Research, focusing on developmental and molecular pathways, and a Ph.D. from Caltech, where research centered on O-GlcNAc glycosylation in neurodegenerative disease. Andrew's academic foundation includes a Bachelor's degree in Chemical Biology from the University of California, Berkeley.